|
Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types. |
|
|
Consulting or Advisory Role - Dara Biosciences; Genentech; Samus Therapeutics |
|
|
Consulting or Advisory Role - Genentech/Roche (Inst); Pfizer (Inst); Sanofi (Inst) |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Oncothyreon (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst) |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Boehringer Ingelheim; Genentech; Novartis |
Research Funding - Florida Cancer Specialists |
|
|
Research Funding - Novartis |
|
|
Honoraria - Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Synta |
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Synta (Inst) |
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA. |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; Roche; Synta |
|
|
Research Funding - Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Teva (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advaxis; Amgen (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); Merrimack |
|
|
|
|
Stock and Other Ownership Interests - Gradalis |
|
Consulting or Advisory Role - Amgen |
|
Patents, Royalties, Other Intellectual Property - Gradalis |
Travel, Accommodations, Expenses - Amgen; Baxalta; Takeda |
|
|
Research Funding - AstraZeneca |
|
|
Honoraria - Gilead Sciences; Medivation; Taiho Pharmaceutical |
Speakers' Bureau - Gilead Sciences; Medivation; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caris Life Sciences |
Research Funding - Amgen; AstraZeneca; Genentech; Lilly; Merck; Millennium; Polynoma |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
Research Funding - Roche/Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche/Genentech |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Sanofi |
|
|
Stock and Other Ownership Interests - Apogenix; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma |
Consulting or Advisory Role - Infinity Pharmaceuticals; Juno Therapeutics; Lilly; PMV Pharma |
Travel, Accommodations, Expenses - Novartis; Roche/Genentech |